Antimicrobial therapy of nonspecific vaginitis and cervicitis: Experience with the use of josamycin

There is a significant increase in the incidence of nonspecific vaginitis and cervicitis caused by non-classical pathogens in current gynecological practice. This trend is accompanied by an expansion of the infectious agent spectrum, including gram-negative aerobes, non-clostridial anaerobes, and mycoplasmas, which results in the increased incidence of mixed diseases. Despite the diversity of therapeutic strategies, particular attention of researchers was directed to the development of effective treatments for mixed nonspecific vaginitis and cervicitis, due to insufficient efficacy of the current treatment regimens contributing to the recurrence of the pathological process. Microbial associations produce virulence factors that promote infectivity of each microorganism and improve their resistance to external effects, including drug therapy. This article presents the results of our study demonstrating a significant increase in the prevalence of nonspecific vaginal infections among women in the Krasnodar Krai. We have analysed clinical case reports and features of the therapy of mixed nonspecific vaginitis and cervicitis with due account for the sensitivity of vaginal microbiota to etiotropic therapy. Clinical cases include the use of modern etiotropic therapy aimed at the rational elimination of pathogens using mixed-activity drugs, preferably bacteriostatic, which are best known for their minimal effect on the normal vaginal microbiota and high patient compliance. The active introduction of drugs with proven efficacy and safety into clinical practice helps improve the patients' ability to adhere to prescribed therapies, reduce the risk of non-specific vaginal infection recurrence, and minimize complications involving reproductive disorders. The experience with Vilpramycin SAR® has demonstrated its high clinical efficacy, low resistance of microorganisms and high tolerability, owing to its orodispersible dosage form, which makes it a universal remedy for the treatment of mixed infections in the female lower genital tract.

1. Prilepskaya VN, Abakarova PR, Mukhambetalieva DD. Vulvovaginal infections and women’s health. Effective Pharmacotherapy. 2020;16(7):40–46. (In Russ.) Available at: https://umedp.ru/articles/vulvovaginalnye_ infektsii_i_zhenskoe_zdorove.html.

2. Dobrokhotova YuE, Markova EA. Mixed vaginitis. What’s new? Features of the course and therapy of mixed vaginitis. Russian Journal of Human Reproduction. 2022;28(4):137–144. (In Russ.) https://doi.org/10.17116/repro202228041137.

3. Tevlin KP, Khanaliev BV, Tevlina EV. Bacterial vaginosis as a risk factor for lower urinary tract infection in women: case report. Gynecology. 2022;24(2):140–143. https://doi.org/10.26442/20795696.2022.2.201411.

4. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020;19(1):5. https://doi.org/10.1186/s12941-020-0347-4.

5. Drozhdina MB. Vaginal microbiota, immune response and some sexually transmitted infections: mechanisms of interaction and regulation of the vaginal ecosystem. Klinicheskaya Dermatologiya i Venerologiya. 2020;19(6):926–933. (In Russ.) https://doi.org/10.17116/klinderma202019061926.

6. Sozonova EA, Chapova NE, Budanova EV. Dynamic changes in the women’s vaginal microbiota. Gynecology, Obstetrics and Perinatology. 2021;20(4):106–114. (In Russ.) https://doi.org/10.20953/1726-1678-2021-4-106-114.

7. Vagios S, Mitchell CM. Mutual Preservation: A Review of Interactions Between Cervicovaginal Mucus and Microbiota. Front Cell Infect Microbiol. 2021;11:676114. https://doi.org/10.3389/fcimb.2021.676114.

8. Saadaoui M, Singh P, Ortashi O, Al Khodor S. Role of the vaginal microbiome in miscarriage: exploring the relationship. Front Cell Infect Microbiol. 2023;13:1232825. https://doi.org/10.3389/fcimb.2023.1232825.

9. Dobrokhotova YuE, Borovkova EI, Hertek SE, Koroleva VI. Bacterial vaginosis in the first trimester of pregnancy: microbiological and immunological indicators in the evaluation of therapy efficiency. Akusherstvo i Ginekologiya (Russian Federation). 2020;(6):98–104. (In Russ.) https://doi.org/10.18565/aig.2020.6.98-104.

10. Zhou ZW, Long HZ, Cheng Y, Luo HY, Wen DD, Gao LC. From Microbiome to Inflammation: The Key Drivers of Cervical Cancer. Front Microbiol. 2021;12:767931. https://doi.org/10.3389/fmicb.2021.767931.

11. Apolikhina IA, Gorbunova EA, Efendieva ZN. Modern treatment options for mixed and aerobic vaginitis. Meditsinskiy Sovet. 2022;16(5):137–143. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-5-137-143.

12. Olina AA, Meteleva TA. Current possibilities in the treatment of nonspecific vaginal infectious diseases. Russian Bulletin of ObstetricianGynecologist. 2016;16(6):89–94. (In Russ.) https://doi.org/10.17116/rosakush201616689-94.

13. Rogozhina IE, Neufeld IV, Stolyarova UV, Skupova IN. Treatment optimization in women with recurrent vaginitis and nonspecific cervicitis. Infectious Diseases: News, Opinions, Training. 2017;(1):70–75. (In Russ.) https://doi.org/10.24411/2305-3496-2017-00025.

14. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24(12):1241–1248. https://doi.org/10.1002/pds.3900.

15. Borovikov IO, Kutsenko II, Bulgakova VP, Rubinina EhR, Gorring KhI. Mixed non-specific vaginal infections: the experience with topical therapy. Russian Journal of Woman and Child Health. 2020;3(4):221–227. (In Russ.) Available at: https://www.rmj.ru/articles/ginekologiya/Smeshannye_nespecificheskie_infekcionnye_zabolevaniya_vlagalischa_opyt_lokalynoy_terapii/.

16. Odyvanova AA, Mezhevitinova EA, Prilepskaya VN, Donnikov AE, Uruymagova AT, Abakarova PR et al. Modern ideas about the etiology, pathogenesis, diagnosis and treatment of chronic nonspecific cervicitis. Meditsinskiy Sovet. 2022;(14):178–184. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-14-178-184.

17. Pestrikova TYu, Astafieva AS, Yurasova EA. The effectiveness of treatment of cervicitis of nonspecific etiology depending on concomitant pathology of the urogenital tract: results of a five-year study. Women’s Health and Reproduction. 2023;(6). (In Russ.) Available at: https://journalgynecology.ru/statyi/effektivnost-lecheniya-cervicita-nespecificheskoj-etiologii-v-zavisimosti-ot-soputstvujushhej-patologii-urogenitalnogo-traktarezultaty-pyatiletnego-issledovaniya.

18. Shikh EV, Makhova AA. A security issue. Non Nocere. New Therapeutic Journal. 2025;(7):18–28. (In Russ.) Available at: https://www.mediasphera.ru/issues/non-nocere/2025/7/1265864282025071018.